<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: In type 2 diabetic patients, persistence of <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> has been reported as a cause of increased production of oxygen free radicals (FR), which leads to <z:mp ids='MP_0003674'>oxidative stress</z:mp> (OS) and becomes the main factor for predisposition to the cardiovascular complications in <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Diabetic postmenopausal women are prone to <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> due to reduced production of <z:chebi fb="0" ids="50114">estrogen</z:chebi> which is a potent <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and prevents <z:mp ids='MP_0003674'>oxidative stress</z:mp> (OS) in body </plain></SENT>
<SENT sid="2" pm="."><plain>The study is being aimed to find out the status of <z:chebi fb="11" ids="22586">antioxidant</z:chebi> enzymes (AOEs) and malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>) in post-menopausal diabetic women </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: The study was conducted with a total of 70 cases, which included 35 Type 2 diabetic post-menopausal females (45 - 60 years) with diabetic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> complication as the study group and 35 age matched type 2 diabetic postmenopausal females without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> complication </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> diabetic post menopausal females with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> had significantly higher levels of fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG), postprandial plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (PPPG), total cholesterol (TC), <z:chebi fb="0" ids="17855">triglyceride</z:chebi> (TG), <z:chebi fb="1" ids="47774">low density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>), <z:chebi fb="0" ids="47773">very low density lipoprotein cholesterol</z:chebi> (<z:chebi fb="0" ids="47773">VLDL-C</z:chebi>), catalase (CAT), and malondialdehyde (<z:chebi fb="14" ids="32506">MDA</z:chebi>) and significantly lower levels of <z:chebi fb="0" ids="47775">HDL-C</z:chebi>, reduced <z:chebi fb="0" ids="16856">glutathione</z:chebi> (GSH), <z:chebi fb="0" ids="16856">glutathione</z:chebi> reductase (GR), <z:chebi fb="0" ids="16856">glutathione</z:chebi> peroxidase (GPx), and <z:chebi fb="1" ids="18421">superoxide</z:chebi> dismutase (SOD) as compared to the levels of control subjects </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: During menopause, reduced production of <z:chebi fb="0" ids="50114">estrogen</z:chebi> causes <z:hpo ids='HP_0002155'>hypertriglyceridemia</z:hpo>, <z:hpo ids='HP_0003124'>hypercholesterolemia</z:hpo>, and <z:hpo ids='HP_0010980'>hyperlipoproteinemia</z:hpo> whose oxidation causes the accumulation of FR in the cell, which precipitates OS </plain></SENT>
<SENT sid="6" pm="."><plain>Also, type 2 diabetic subjects with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> poor glycemic control and impaired AOEs result in increased oxidative injury by failure of protective mechanisms, which further leads to <z:mp ids='MP_0003674'>oxidative stress</z:mp> </plain></SENT>
</text></document>